Volume | 4,345,974 |
|
|||||
News | - | ||||||
Day High | 1.43 | Low High |
|||||
Day Low | 1.30 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
X4 Pharmaceuticals Inc | XFOR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.43 | 1.30 | 1.43 | 1.39 | 1.41 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
11,768 | 4,345,974 | $ 1.34 | $ 5,839,473 | - | 0.5723 - 2.575 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:25:37 | formt | 1,000 | $ 1.37 | USD |
X4 Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
230.86M | 167.29M | - | 0 | -96.41M | -0.58 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
X4 Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XFOR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.03 | 1.60 | 1.03 | 1.40 | 7,540,507 | 0.34 | 33.01% |
1 Month | 0.93 | 1.60 | 0.82 | 1.20 | 3,362,213 | 0.44 | 47.31% |
3 Months | 0.8373 | 1.60 | 0.7004 | 1.06 | 1,997,199 | 0.5327 | 63.62% |
6 Months | 1.08 | 1.60 | 0.5723 | 0.9002013 | 2,129,683 | 0.29 | 26.85% |
1 Year | 0.80 | 2.575 | 0.5723 | 1.34 | 2,615,053 | 0.57 | 71.25% |
3 Years | 9.15 | 9.96 | 0.5723 | 1.55 | 1,239,043 | -7.78 | -85.03% |
5 Years | 18.36 | 22.50 | 0.5723 | 1.87 | 769,629 | -16.99 | -92.54% |
X4 Pharmaceuticals Description
X4 Pharmaceuticals Inc is clinical-stage biopharmaceutical company. It is focused on restoring the immune system function by developing therapeutics for the treatment of rare diseases. Its molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. Its product candidate, X4P-001, has completed a Phase 2 trial in patients with a rare genetic PI called Warts. The company is also developing X4P-002, a CXCR4 antagonist that has properties that could enable penetration of the blood-brain barrier and provide appropriate therapeutic exposures to treat brain cancers, including glioblastoma multiforme. |